The effects of amphetamines on gene expression in zebrafish have been uncovered. This new study, published in BioMed Central's open access journal Genome Biology, provides clues to the genetics that underlie susceptibility to addiction by describing the nad zebrafish mutant, which does not feel the rewarding effects of the drugs.
Katharine Webb, from the German Research Center for Environmental Health, Helmholtz Zentrum München, worked with an international team of researchers to carry out the experiments. She said, "Addictive drugs all trigger a sequence of widespread long-lasting consequences on brain physiology, most of which are only partially understood. Because a major step in the development of addiction is the switch from drug use to drug abuse, we aimed to gain insight into the mechanisms triggering the initiation of addictive behaviour".
The team used the mutagenic chemical ENU to generate hundreds of mutant zebrafish. From these, they bred a line that did not respond to amphetamine administration (despite the presence of the drug in the fish's brain) but that appeared to be normal in all other ways. As amphetamine is experienced as pleasurable, amphetamine response was determined by measuring whether fish chose to move to a half of the tank where the drug had been given out.
By comparing these drug-proof nad mutants to fish with a normal response, Webb and her colleagues discovered a set of 139 genes that respond inappropriately to amphetamine in nad mutants, without being altered under normal conditions in either genotype. In addition to genes involved in pathways classically associated with reward, this gene set shows a striking enrichment in transcription factors that are specifically known for their involvement in brain development. Even more interestingly, as the authors demonstrate, several of these genes are expressed in neurogenic domains of the adult fish brain – these are domains where neurons are generated from neural stem cells during adulthood. According to the researchers, " These factors, which are also dramatically down-regulated by amphetamine, can serve as valuable new entry points into studying the link between adult neurogenesis and addiction".
These results identify a new network of coordinated gene regulation that influences the response to amphetamine and may underlie the susceptibility to addiction.
Notes to Editors
1. Zebrafish reward mutants reveal novel transcripts mediating the behavioral effects of amphetamine
Katharine J Webb, William HJ Norton, Dietrich Trümbach, Annemarie H Meijer, Jovica Ninkovic, Stefanie Topp, Daniel Heck, Carsten Marr, Wolfgang Wurst, Fabian J Theis, Herman P Spaink and Laure Bally-Cuif
Genome Biology (in press)
During embargo, article available here: http://genomebiology.com/imedia/3771266602751577_article.pdf?random=576849
After the embargo, article available at journal website: http://genomebiology.com/
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at firstname.lastname@example.org on the day of publication
2. For further information please read the minireview highlighting this work:
Amphetamine recapitulates developmental programs in the zebrafish
Jean Lud Cadet
Genome Biology (in press)
3. Genome Biology publishes articles from the full spectrum of biology. Subjects covered include any aspect of molecular, cellular, organismal or population biology studied from a genomic perspective, as well as genomics, proteomics, bioinformatics, genomic methods (including structure prediction), computational biology, sequence analysis (including large-scale and cross-genome analyses), comparative biology and evolution.
4. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.